PRLD GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Prelude Therapeutics Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Prelude Therapeutics Inc
Did you know?
Holds 2.2x more cash than debt — a strong balance sheet.
Current Price
$4.74
+0.85%GoodMoat Value
$0.97
79.6% overvaluedProfile
Valuation (TTM)
Market Cap$297.98M
P/E-2.99
EV—
P/B4.34
Shares Out62.87M
P/Sales24.55
Revenue$12.14M
EV/EBITDA—
Prelude Therapeutics Inc (PRLD) Quality Analysis
PRLD Profitability
Profitability trend analysis coming soon
PRLD Growth
Growth trend analysis coming soon
PRLD Financial Health
Financial health indicators coming soon
PRLD Quality & Fundamental Analysis
Prelude Therapeutics Inc (PRLD) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Prelude Therapeutics Inc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Prelude Therapeutics Inc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of -819.59% and a return on equity (ROE) of -144.96%. Return on assets (ROA) stands at -70.41%.
The debt-to-equity ratio is 0.26, with a current ratio of 1.99. Operating margin is -861.33%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Prelude Therapeutics Inc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.